Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

Spyre Therapeutics (SYRE) reported that its anti-IL-23 antibody, SPY003, met primary endpoints in a Phase 2 trial, showing a 10.0-point reduction in Robart’s Histopathology Index score. This follows successful results for SPY001 and SPY002, completing proof-of-concept for all three molecules in its IBD portfolio. The company has $1.1 billion in cash, enough to fund operations into 2029. Part B of the SKYLINE trial, testing drug combinations, is still enrolling, with data expected in 2027. Spyre

Guggenheim named Spyre Therapeutics (SYRE) its top biotech pick after positive Phase II trial data for SPY003, showing 20% clinical remission in ulcerative colitis. The firm highlights durability as a key advantage. Part B of the study is enrolling, with results expected in 2027. Guggenheim maintains a positive rating despite a recent downgrade from Wolfe Research.

Guggenheim maintains a buy rating on Spyre Therapeutics, citing positive Phase II SKYWAY-RA results for SPY072, despite discontinuing the rheumatoid arthritis program. The firm projects the stock to settle in the $90-95 range, with valuation based on the inflammatory bowel disease program. Other analysts have mixed views, with Wolfe Research downgrading and Mizuho raising its price target to $120.

Spyre Therapeutics (SYRE) reported mixed Phase II SKYWAY-RA study results for SPY072 in rheumatoid arthritis. While the low dose met the primary endpoint, the high dose did not. The company will shift focus to broader autoimmune indications and combination therapies. SYRE shares fell 4% in after-hours trading.

Spyre Therapeutics (SYRE) stock fell 11.7% in pre-market trading after Phase 2 trial data for SPY072 in rheumatoid arthritis showed statistically significant but insufficient efficacy to advance as a monotherapy. Wedbush maintained an Outperform rating with a $130 target. The company plans further readouts in 2026 for other indications. The decline is attributed to the clinical news, not broader market trends.

Spyre Therapeutics (SYRE) reported mixed Phase 2 results for SPY072 in rheumatoid arthritis, showing efficacy but not meeting monotherapy targets. Both doses showed statistically significant benefits over placebo on some endpoints. The company plans to release data on other trials in 2026-2028. Wedbush maintains an outperform rating with a $130 price target. SYRE shares are down 4.06% in overnight trading.